ARTICLE | Emerging Company Profile
Splice Bio: gene therapies that reassemble large proteins in vivo
Spain’s largest-ever biotech series A goes to Ysios-backed Splice Bio, which uses inteins to reconstitute large proteins
February 16, 2022 8:45 PM UTC
Gene therapy company Splice Bio has attracted the largest series A funding in history for a Spanish biotech as it advances a lead ophthalmology program using a splicing technique to deliver large genetic payloads via AAV vectors.
Barcelona-based Splice Bio S.L. won the backing of lead investors UCB Ventures and Ysios Capital in its new €50 million ($56.6 million) series A round, which arrives about 17 months after the biotech rebranded behind technology spun out from chemistry professor Tom Muir’s laboratory at Princeton University...